2012年12月2日 訊 /生物谷BIOON/ --近日,，來自英國(guó)的研究者通過研究開發(fā)出的一種新型的微陣列技術(shù),，研究者在實(shí)驗(yàn)中評(píng)估了這種新型的微陣列技術(shù)對(duì)于檢測(cè)廣泛的革蘭氏陰性致病菌抗生素耐藥性基因上的效用。相關(guān)研究報(bào)告“Evaluation of an expanded microarray for detecting antibiotic resistance genes in a broad range of Gram-negative bacterial pathogens.”刊登在了11月5日的國(guó)際雜志Antimicrobial Agents and Chemotherapy上,。
這種新型的微陣列技術(shù)可以檢測(cè)包括19個(gè)不同的抗生素家族及75個(gè)臨床相關(guān)的抗生素耐藥性基因,，并且可以對(duì)132個(gè)革蘭氏陰性致病菌進(jìn)行檢測(cè)。微陣列技術(shù)所揭示的抗生素耐藥性的表型陽性結(jié)果大于91%,，檢測(cè)特異性大于83%,。而且未包括相關(guān)耐藥性表型的微陣列技術(shù)陽性結(jié)果與PCR所得的結(jié)果匹配結(jié)果為94%，這也就表明了,，無論是基因表達(dá)強(qiáng)度低還是不存在,，通過微陣列檢測(cè)出的細(xì)菌耐藥基因的結(jié)果是可信的。
對(duì)于一些抗菌耐藥性系列所得的微陣列結(jié)果的低靈敏度以及陰性預(yù)測(cè)值,，研究者Roderick Card說,，這有可能是由于抗性基因數(shù)量的限制所導(dǎo)致的，或者是耐藥基因發(fā)生了突變所引發(fā)的,。
這種新型微陣列技術(shù)可用于臨床上的診斷,，來幫助醫(yī)生們采取正確的治療手段來治療由于耐藥性革蘭氏陰性致病菌的感染，對(duì)于治療那些因?yàn)榀煼ㄊ〉牟∪擞幸欢ǖ膸椭?。（生物谷Bioon.com）
PMC:
PMID:
Evaluation of an expanded microarray for detecting antibiotic resistance genes in a broad range of Gram-negative bacterial pathogens.
Card R, Zhang J, Das P, Cook C, Woodford N, Anjum MF.
A microarray capable of detecting 75 clinically-relevant antibiotic resistance genes, encompassing 19 different antimicrobial classes, was tested on 132 Gram-negative bacteria. Microarray-positive results correlated >91% with antimicrobial resistance phenotypes, assessed using British Society for Antimicrobial Chemotherapy clinical breakpoints; the overall test specificity was >83%. Microarray-positive results without a corresponding resistance phenotype matched 94% with PCR, indicating accurate detection of genes present in the respective bacteria by microarray when expression was low or absent, and hence undetectable by susceptibility testing. The low sensitivity and negative predictive values of the microarray results for identifying resistance to some antimicrobial resistance classes is likely due to the limited number of resistance genes present on the current microarray for those antimicrobial agents, or to mutation-based resistance mechanisms. With regular updates, this microarray can be used for clinical diagnostics to help accurate therapeutic options to be taken following infection with multi-antibiotic resistant Gram-negative bacteria and prevent treatment failure.
